A controlled trial of prophylactic granulocyte transfusions during induction chemotherapy for acute nonlymphoblastic leukemia. 1984

J L Gomez-Villagran, and A Torres-Gómez, and P Gomez-Garcia, and F Martinez-Guibelalde, and F Velasco-Jimena

Thirty-five noninfected patients undergoing induction chemotherapy for acute nonlymphoblastic leukemia (ANLL) were randomized to either receive (19 patients) or not receive (16 control patients) prophylactic granulocyte transfusions (PGT) when their granulocyte count fell below 0.5 X 10(9)/1. Both groups received identical anti-infectious and supportive care except for granulocyte transfusions. The authors found a nonstatistically significant decrease of the infection rate in the prophylactic group. However, the bacteriologically documented infections and septicemia incidence was significantly higher in the control than in the prophylactic group (P less than 0.05). In the control group they observed in 8 of 16 cases life-threatening infections in contrast with only 1 case in the prophylactic group (P less than 0.01). A significant reduction of deaths due to infectious causes in the prophylactic versus control group were also found (P less than 0.05). The authors did not find an increase of pneumonia or pulmonary infiltrates in the patients belonging to prophylactic in comparison to control group.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal

Related Publications

J L Gomez-Villagran, and A Torres-Gómez, and P Gomez-Garcia, and F Martinez-Guibelalde, and F Velasco-Jimena
September 1981, The New England journal of medicine,
J L Gomez-Villagran, and A Torres-Gómez, and P Gomez-Garcia, and F Martinez-Guibelalde, and F Velasco-Jimena
May 1981, Annals of internal medicine,
J L Gomez-Villagran, and A Torres-Gómez, and P Gomez-Garcia, and F Martinez-Guibelalde, and F Velasco-Jimena
January 1982, Transfusion,
J L Gomez-Villagran, and A Torres-Gómez, and P Gomez-Garcia, and F Martinez-Guibelalde, and F Velasco-Jimena
January 1982, The New England journal of medicine,
J L Gomez-Villagran, and A Torres-Gómez, and P Gomez-Garcia, and F Martinez-Guibelalde, and F Velasco-Jimena
October 1981, Annals of internal medicine,
J L Gomez-Villagran, and A Torres-Gómez, and P Gomez-Garcia, and F Martinez-Guibelalde, and F Velasco-Jimena
March 1977, The New England journal of medicine,
J L Gomez-Villagran, and A Torres-Gómez, and P Gomez-Garcia, and F Martinez-Guibelalde, and F Velasco-Jimena
January 1982, Progress in clinical and biological research,
J L Gomez-Villagran, and A Torres-Gómez, and P Gomez-Garcia, and F Martinez-Guibelalde, and F Velasco-Jimena
March 2011, Cancer,
J L Gomez-Villagran, and A Torres-Gómez, and P Gomez-Garcia, and F Martinez-Guibelalde, and F Velasco-Jimena
January 1975, Cancer chemotherapy reports,
J L Gomez-Villagran, and A Torres-Gómez, and P Gomez-Garcia, and F Martinez-Guibelalde, and F Velasco-Jimena
March 1972, Annals of internal medicine,
Copied contents to your clipboard!